Patents by Inventor Michael Dragunow

Michael Dragunow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
    Patent number: 7605177
    Abstract: This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: October 20, 2009
    Assignee: Neuren Pharmaceuticals Limited
    Inventors: Peter David Gluckman, Gregory Brian Thomas, Jian Guan, Michael Dragunow, Ashmit Kumar Anand, Frank Sieg, Margaret Anne Brimble
  • Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
    Publication number: 20070298009
    Abstract: This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.
    Type: Application
    Filed: December 20, 2005
    Publication date: December 27, 2007
    Applicant: NEUREN PHARMACEUTICALS LIMITED
    Inventors: Peter Gluckman, Gregory Thomas, Jian Guan, Michael Dragunow, Ashmit Anand, Nicole de Rosbo, Frank Sieg, Margaret Brimble